Literature DB >> 22180071

Association of CYP2C19*3 gene polymorphism with breast cancer in Chinese women.

C Q Gan1, X Y Wang, Y D Cao, W X Ye, H Liu, Y Y Sun.   

Abstract

Cytochrome P450 (CYP) 2C19 metabolizes arachidonic acid to biologically active epoxyeicosatrienoic acids, which significantly promote proliferation of cancer cells in vitro and in vivo. We looked for a possible association between human CYP2C19*3 gene polymorphism and breast cancer in the Chinese Han population. In a Chinese Han case-control study of breast cancer patients (N = 600) and age- and gender-matched healthy controls (N = 600), we investigated polymorphism in the CYP2C19 gene by PCR-RFLP analysis. The CYP2C19*3 AG + AA genotype was significantly more prevalent in breast cancer patients than in control subjects (6.67 vs 3.00%; P = 0.003). The odds ratio for carriers of AG + AA genotype for breast cancer was 2.31 (95% confidence interval = 1.27-4.43). Among patients, estrogen receptor, tumor size, histologic grade, presence of primary lymphonode metastases, progesterone receptor positivity, and age at diagnosis were not found to be significantly associated with CYP2C19*3 genotypes (all P > 0.05). We conclude that the CYP2C19*3 gene polymorphism is associated with breast cancer risk in Chinese Han women.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22180071     DOI: 10.4238/2011.December.5.3

Source DB:  PubMed          Journal:  Genet Mol Res        ISSN: 1676-5680


  11 in total

1.  Individuals having variant genotypes of cytochrome P450 2C19 are at increased risk of developing primary liver cancer in Han populations, without infection with the hepatitis virus.

Authors:  Qiao-Yan Li; Ning-Min Zhao; Lian-Cai Wang; Hong-Fei Duan; Yong-Cheng Ma; Wei Zhang; Hong-Wei Zhao; Yu-Hua Qin
Journal:  Tumour Biol       Date:  2014-06-07

2.  Functional polymorphism of CYP2B6 G15631T is associated with hematologic and cytogenetic response in chronic myeloid leukemia patients treated with imatinib.

Authors:  Yaya Kassogue; Meryem Quachouh; Hind Dehbi; Asma Quessar; Said Benchekroun; Sellama Nadifi
Journal:  Med Oncol       Date:  2013-11-29       Impact factor: 3.064

3.  Interaction between smoking and CYP2C19*3 polymorphism increased risk of lung cancer in a Chinese population.

Authors:  Fei Yan; Jin-Fu Xu; Xiao-fang Liu; Xing-Hua Li
Journal:  Tumour Biol       Date:  2014-02-09

4.  Association of cytochrome P450 genetic polymorphisms with neoadjuvant chemotherapy efficacy in breast cancer patients.

Authors:  Tatyana A Seredina; Olga B Goreva; Valeria O Talaban; Alevtina Yu Grishanova; Vyacheslav V Lyakhovich
Journal:  BMC Med Genet       Date:  2012-06-15       Impact factor: 2.103

Review 5.  Poor metabolizers at the cytochrome P450 2C19 loci is at increased risk of developing cancer in Asian populations.

Authors:  Hong Wang; Kang Song; Zenggan Chen; Yanmin Yu
Journal:  PLoS One       Date:  2013-08-27       Impact factor: 3.240

6.  Physical Confirmation and Comparative Genomics of the Rat Mammary carcinoma susceptibility 3 Quantitative Trait Locus.

Authors:  Saasha Le; Zachary C Martin; David J Samuelson
Journal:  G3 (Bethesda)       Date:  2017-06-07       Impact factor: 3.154

7.  The effects of cytochrome P450 2C19 polymorphism on the metabolism of voriconazole in vitro.

Authors:  Ren-Ai Xu; Er-Min Gu; Teng-Hui Liu; Qiu-Geng Ou-Yang; Guo-Xin Hu; Jian-Ping Cai
Journal:  Infect Drug Resist       Date:  2018-11-01       Impact factor: 4.003

Review 8.  Cytochrome P450: Implications for human breast cancer.

Authors:  Bin Luo; Dandan Yan; Honglin Yan; Jingping Yuan
Journal:  Oncol Lett       Date:  2021-05-24       Impact factor: 2.967

9.  Polymorphisms of Phase I and Phase II Enzymes and Breast Cancer Risk.

Authors:  Christina Justenhoven
Journal:  Front Genet       Date:  2012-11-28       Impact factor: 4.599

10.  Polymorphisms in Phase I (CYP450) Genes CYP1A1 (rs4646421), CYP1B1 (rs1056836), CYP19A1 (rs749292) and CYP2C8 (rs1058930) and Their Relation to Risk of Breast Cancer: A Case-Control Study in Mazandaran Province in North of Iran.

Authors:  Golpar Golmohammadzadeh; Abbas Mohammadpour; Nematollah Ahangar; Mohammad Shokrzadeh
Journal:  Open Access Maced J Med Sci       Date:  2019-08-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.